Physiological role of endothelin-1 in flow-mediated vasodilatation in humans and impact of cardiovascular risk factors
暂无分享,去创建一个
V. Richard | C. Thuillez | R. Joannidés | J. Bellien | C. Vendeville | C. Monteil | I. Rémy‐Jouet | C. Roche | T. Duflot | M. Iacob | L. Gutierrez
[1] R. Cannon,et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. , 1999, Hypertension.
[2] A. Quyyumi,et al. Endogenous Endothelin in Human Coronary Vascular Function: Differential Contribution of Endothelin Receptor Types A and B , 2007, Hypertension.
[3] D. Webb,et al. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. , 1999, Hypertension.
[4] R. Cannon,et al. Increased activity of endogenous endothelin in patients with hypercholesterolemia. , 2000, Journal of the American College of Cardiology.
[5] D. Webb,et al. Systemic ETA receptor antagonism with BQ‐123 blocks ET‐1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men , 2001, British journal of pharmacology.
[6] G. Kenny,et al. Endothelin‐1 modulates methacholine‐induced cutaneous vasodilatation but not sweating in young human skin , 2016, The Journal of physiology.
[7] D. Webb,et al. Contribution of endogenous generation of endothelin-1 to basal vascular tone , 1994, The Lancet.
[8] C. DeSouza,et al. Sex Steroids and Gender in Cardiovascular-Renal Physiology and Pathophysiology Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults , 2010 .
[9] W E Haefeli,et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. , 1995, Circulation.
[10] C. Thuillez,et al. Epoxyeicosatrienoic Acids Contribute With Altered Nitric Oxide and Endothelin-1 Pathways to Conduit Artery Endothelial Dysfunction in Essential Hypertension , 2012, Circulation.
[11] D. Webb,et al. Endogenous Endothelin-1 Limits Exercise-Induced Vasodilation in Hypertensive Humans , 2002, Hypertension.
[12] Gian Paolo Rossi,et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. , 2005, Journal of hypertension.
[13] T. Nagase,et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Tardif,et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. , 1998, American heart journal.
[15] J. Panza,et al. Sex-Specific Effects of Cardiovascular Risk Factors on Endothelium-Dependent Dilation and Endothelin Activity in Middle-Aged Women and Men , 2015, PloS one.
[16] C. DeSouza,et al. Endothelin-1 Vasoconstrictor Tone Increases With Age in Healthy Men But Can Be Reduced by Regular Aerobic Exercise , 2007, Hypertension.
[17] T. Lüscher,et al. ETA Receptors Mediate Vasoconstriction of Large Conduit Arteries During Reduced Flow in Humans , 2003, Journal of cardiovascular pharmacology.
[18] R. Khalil,et al. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. , 2012, Biochemical pharmacology.
[19] J. Lindström,et al. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. , 2003, Clinical science.
[20] D. Webb,et al. Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade Mediated Vasodilatation Is Attenuated by Inhibition of − Endothelin-A Receptor Antagonist , 1998 .
[21] T. Fukami,et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. , 1992, Life sciences.
[22] R. Talanow,et al. Regulation of the endothelin system by shear stress in human endothelial cells , 2000, The Journal of physiology.
[23] L. Edvinsson,et al. Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease , 2009, BMC cardiovascular disorders.
[24] D. Webb,et al. Endothelium-derived endothelin-1 , 2010, Pflügers Archiv - European Journal of Physiology.
[25] F. Ruschitzka,et al. Mental Stress Induces Prolonged Endothelial Dysfunction via Endothelin-A Receptors , 2002, Circulation.
[26] A. Davenport,et al. Endothelin‐2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer , 2013, British journal of pharmacology.
[27] P. Walker,et al. Vascular Remodeling in the Internal Mammary Artery Graft and Association With In Situ Endothelin-1 and Receptor Expression , 2006, Circulation.
[28] K. Pyke,et al. Flow-mediated dilation stimulated by sustained increases in shear stress: a useful tool for assessing endothelial function in humans? , 2017, American journal of physiology. Heart and circulatory physiology.
[29] D. Webb,et al. Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography , 2000, Heart.
[30] J. Rouleau,et al. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. , 1998, Circulation.
[31] P. Ganz,et al. Role of Endothelin-1 in the Active Constriction of Human Atherosclerotic Coronary Arteries , 2001, Circulation.
[32] Sadao Kimura,et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.
[33] V. Richard,et al. Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans. , 2015, Kidney international.
[34] M. Omata,et al. Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. , 1999, Circulation.
[35] M. Turina,et al. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. , 1996, Journal of cardiovascular pharmacology.